Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Global Clean Energy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares Global Clean Energy ETF trades at $16.42 (market cap $2.21B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and iShares Global Clean Energy ETF is more actively traded (6,641,356 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Global Clean Energy ETF for 88 Days on average.
| DYN | ICLN | |
|---|---|---|
Market Cap | $2.86B | $2.21B |
Volume | 3,341,579 | 6,641,356 |
Sector | Health | — |
52-Week High | $26.78 | $23.75 |
52-Week Low | $14.60 | $16.00 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ICLN is trading at $16.64, down 2.8% today amid bearish technical signals with 15 sell indicators versus 1 buy. The ETF faces headwinds from clean energy sector volatility, having experienced a 57.2% maximum drawdown historically. Recent news highlights competition from traditional energy ETFs delivering stronger returns with lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains cautious due to high volatility and expense ratio disadvantages versus fossil fuel alternatives. Key risks include sector competition and regulatory uncertainty, while potential catalysts include increased global renewable investment and data center energy demand growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
